Close

Canaccord Genuity Reiterates a 'Hold' on Protalix BioTherapeutics (PLX); Modest U.S. But Strong In Israel

June 25, 2012 8:34 AM EDT Send to a Friend
Canaccord Genuity reiterates a 'Hold' on Protalix BioTherapeutics (NYSE: PLX) price target of $6.00 (from $8.00).

Analyst, Ritu Baral ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login